Search

Your search keyword '"Geredeli, Caglayan"' showing total 181 results
Start Over Author "Geredeli, Caglayan"
181 results on '"Geredeli, Caglayan"'

2. The results of adding immunotherapy to chemotherapy in patients with small cell lung cancer: Registurk-Lung study—Real-world data.

Author

Cil, Timucin, primary, Hacibekiroglu, Ilhan, additional, Uncu, Dogan, additional, Isikdogan, Abdurrahman, additional, Ates, Ozturk, additional, Sendur, Mehmet Ali Nahit, additional, Bilici, Mehmet, additional, Geredeli, Caglayan, additional, Turk, Haci Mehmet, additional, Cicin, Irfan, additional, Gumus, Mahmut, additional, Bilir, Cemil, additional, Ozcelik, Melike, additional, Coban, Ezgi, additional, Kilickap, Sadettin, additional, Demirag, Guzin, additional, Yildirim, Nilgun, additional, Ozdemir, Feyyaz, additional, Teker, Fatih, additional, and Altinbas, Mustafa, additional

Published
2024
Full Text
View/download PDF

3. Clinicopathologic Features And Efficacy Of Induction Chemotherapy In Nasopharyngeal Carcinoma: Real-World Experience

Author

Majidova, Nargiz, primary, Sari, Murat, additional, Kahvecıglu, Fatma Akdag, additional, Ozcan, Erkan, additional, Akdag, Mutıanur Ozkorkmaz, additional, Dogan, Akıf, additional, Yıldırım, Sedat, additional, Sonusen, Sermın Dınc, additional, Yunusov, Emıl, additional, Yasar, Alper, additional, Celebi, Abdussamet, additional, Sever, Nadıye, additional, Kocaaslan, Erkam, additional, Erel, Pınar, additional, Agyol, Yesım, additional, Guren, Ali Kaan, additional, Arikan, Rukiye, additional, Işık, Selver, additional, Balvan, Ozlem, additional, Geredeli, Caglayan, additional, Uygun, Kazım, additional, Hacıbekiroğlu, Ilhan, additional, Kostek, Osman, additional, and Bayoğlu, İbrahim Vedat, additional

Published
2024
Full Text
View/download PDF

5. Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer

Author

Ilhan, Yusuf, Tatli, Ali Murat, Teker, Fatih, Onder, Arif Hakan, Kose, Fatih, Geredeli, Caglayan, Karaagac, Mustafa, Kaplan, Muhammet Ali, Inanc, Mevlude, Goktas Aydin, Sabin, Kargi, Aysegul, Arak, Hacı, Ozturk, Banu, Besen, Ali Ayberk, Selvi, Oguzhan, Korkmaz, Mustafa, Oruc, Zeynep, Bozkurt, Oktay, Bilici, Ahmet, Bayram, Selami, Dae, Shute Ailia, Ozdogan, Mustafa, Coskun, Hasan Senol, and Sezgin Goksu, Sema

Published
2022
Full Text
View/download PDF

6. Two Randomized Controlled Trials of Romiplostim for Chemotherapy-Induced Thrombocytopenia in Patients with Solid Tumors

Author

Al-Samkari, Hanny, primary, Geredeli, Caglayan, additional, Arslan, Cagatay, additional, Korantzis, Ippokratis, additional, Dogu, Gamze Gokoz, additional, Nechaeva, Marina, additional, Fernandez, Mercedes Salgado, additional, Astorga, Beatriz Gonzalez, additional, Yordanov, Valeriy, additional, Ciuleanu, Tudor-eliade, additional, Bowers, Charles, additional, Armas, Armando, additional, Scotte, Florian, additional, Camargo, Johnny, additional, Muñoz, César, additional, Bunn, Paul, additional, Kuter, David J., additional, and Soff, Gerald A., additional

Published
2022
Full Text
View/download PDF

8. The effect of body mass index on location of recurrence and survival in early-stage colorectal cancer

Author

Sakin, Abdullah, Samanci, Nilay, Secmeler, Saban, Arici, Serdar, Can, Orcun, Yasar, Nurgul, Geredeli, Caglayan, Demir, Cumhur, and Cihan, Sener

Subjects
Oncology, Experimental, Obesity -- Complications and side effects, Colorectal cancer -- Prognosis -- Patient outcomes, Cancer -- Relapse -- Research, Body mass index -- Research, Health
Abstract

Byline: Abdullah. Sakin, Nilay. Samanci, Saban. Secmeler, Serdar. Arici, Orcun. Can, Nurgul. Yasar, Caglayan. Geredeli, Cumhur. Demir, Sener. Cihan Introduction: Obesity has become one of the major public health problems [...]

Published
2020

9. The Prognostic Importance of Microsatellite Instability Status in Turkish Stage II and III Gastric Cancer Patients who Received Adjuvant Chemotherapy

Author

Cekin, Ruhper, Erhan, Selma Sengiz, Arici, Serdar, Cihan, Sener, Sakin, Abdullah, Geredeli, Caglayan, Secmeler, Saban, and Atci, Muhammed Mustafa

Subjects
Oncology, medicine.medical_specialty, Turkish, Adjuvant chemotherapy, business.industry, Microsatellite instability, Cancer, Hematology, Stage ii, medicine.disease, digestive system diseases, language.human_language, Internal medicine, medicine, language, business
Abstract

Some retrospective studies in different populations have evaluated the prognostic value of microsatellite instability status (MSI) in patients with gastric cancer (GC). A small number of studies have focused on the effect of MSI status on the outcome of GC patients who have received adjuvant chemotherapy (CT). Medical records of 318 patients with stage II or III GC who had been treated with adjuvant CT after D2 gastrectomy between 2016 and 2019 were scanned. Eligible patients were divided into two groups: MSI-H and microsatellite stable (MSS). The determinant factors were examined using Cox regression analysis. A statistical significance level of alpha was accepted as p < 0.05. The study included 207 GC patients and 21 (10.1%) MS-high patients. A median disease-free survival was not reached (95% CI NR) in MSI-H patients, whereas a median disease-free survival was 30 months in MSS patients (95% CI 24.3-35.6) (p= 0.046). A median overall survival (OS) was not reached in MSI-H patients, whereas a median overall survival of 46 months (95% CI: 28.8 - 60.1) was reached in MSS patients (p= 0.032). In the multivariate Cox regression analysis for OS, female gender and MSI-H status were positive predictors of OS, whereas stage III disease negatively affected OS (p= 0.009, p= 0.030, and p= 0.009, respectively). Microsatellite instability status may be a prognostic factor in stage II and III Turkish GC patients who have received adjuvant oxaliplatin-based CT.

Published
2021
Full Text
View/download PDF

10. Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer

Author

Goktas Aydin, Sabin, primary, Cakan Demirel, Burcin, additional, Bilici, Ahmet, additional, Topcu, Atakan, additional, Aykan, Musa Barış, additional, Kahraman, Seda, additional, Akbıyık, Ilgın, additional, Atci, Muhammed Mustafa, additional, Olmez, Omer Fatih, additional, Yaren, Arzu, additional, Sendur, Mehmet Ali Nahit, additional, Geredeli, Caglayan, additional, Seker, Mesut, additional, Urun, Yuksel, additional, Karadurmus, Nuri, additional, and Aydin, Ahmet, additional

Published
2022
Full Text
View/download PDF

12. Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wi̇ld-type patients treated with biologics second-line mCRC.

Author

Yildirim, Mahmut Emre, primary, Karaca, Mustafa, additional, Artac, Mehmet, additional, Cicin, Irfan, additional, Geredeli, Caglayan, additional, Alacacioglu, Ahmet, additional, Tanrikulu Simsek, Eda, additional, Bilici, Ahmet, additional, Harputluoglu, Hakan, additional, Ozcelik, Melike, additional, Bozkurt, Oktay, additional, Yuksel, Sinemis, additional, Tural, Deniz, additional, Sakin, Abdullah, additional, Cil, Timucin, additional, Oven, Basak Bala, additional, Dane, Faysal, additional, Cevik, Duygu, additional, Gumus, Mahmut, additional, and Isikdogan, Abdurrahman, additional

Published
2022
Full Text
View/download PDF

13. The prognostic significance of the 18F-fluorodeoxyglucose positron emission tomography/computed tomography in early-stage nonsmall cell lung cancer

Author

Geredeli, Caglayan, Artac, Mehmet, Kocak, Ismail, Koral, Lokman, Sakin, Abdullah, Altinok, Tamer, Kaya, Bugra, and Karaagac, Mustafa

Subjects
Positron emission tomography -- Health aspects, Sport utility vehicles -- Health aspects, Cancer research -- Health aspects, Non-small cell lung cancer -- Care and treatment, Health
Abstract

Byline: Caglayan. Geredeli, Mehmet. Artac, Ismail. Kocak, Lokman. Koral, Abdullah. Sakin, Tamer. Altinok, Bugra. Kaya, Mustafa. Karaagac Context: The prognostic criteria for early-stage nonsmall cell lung cancer (NSCLC) wait to [...]

Published
2020

14. Second-line Therapy after Trastuzumab Failure in HER2-Positive Metastatic Gastric Cancer: A Real-life Data.

Author

Topcu, Atakan, Besiroglu, Mehmet, Atci, Muhammed Mustafa, Secmeler, Saban, Ayhan, Murat, Ozkan, Metin, Bozkurt, Oktay, Urakci, Zuhat, Ay, Seval, Geredeli, Caglayan, Yasin, Ayse Irem, Pasin, Ozge, and Turk, Haci Mehmet

Subjects
THERAPEUTIC use of antineoplastic agents, STOMACH tumors, STATISTICS, FOLINIC acid, CONFIDENCE intervals, ONCOGENES, TRASTUZUMAB, LOG-rank test, METASTASIS, RETROSPECTIVE studies, IRINOTECAN, TREATMENT failure, TREATMENT effectiveness, PEARSON correlation (Statistics), FLUOROURACIL, QUALITATIVE research, SURVIVAL analysis (Biometry), DESCRIPTIVE statistics, KAPLAN-Meier estimator, CHI-squared test, DATA analysis software, PACLITAXEL, PROPORTIONAL hazards models
Abstract

Objectives: To compare the second-line treatments on survival after trastuzumab failure in HER2-positive metastatic gastric cancer. Methods: We retrospectively included 57 patients. Of whom, 32 (56%) received paclitaxel, whereas 25 (44%) received 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI). We analyzed the patient characteristics, and survival outcomes of the second-line treatment. Results: The median PFS was 3.5 months in the paclitaxel-group and 4.8 months in the FOLFIRI-group (p=0.569). The median overall survival (OS) was 6.0 months in paclitaxel-group and 11.0 months in FOLFIRI-group (p=0.410). FOLFIRI provided a significant OS advantage over paclitaxel in patients with grade 3 tumors or who did not have an objective first-line treatment response. Conclusion: FOLFIRI may be recommended as a preferred option over paclitaxel in patients with these identified risk factors. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

16. Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology

Author

Kaplan, Muhammet Ali, Isikdogan, Abdurrahman, Koca, Doğan, Kucukoner, Mehmet, Gumusay, Ozge, Yildiz, Ramazan, Dayan, Adem, Demir, Lütfiye, Geredeli, Caglayan, Kocer, Murat, Arslan, Ulku Yalcintas, İnal, Ali, Akman, Tulay, Coskun, Ugur, Sener, Nur, Inanc, Mevlude, Elkiran, Emin Tamer, Ozdemir, Nuriye Yildirim, Durnalı, Ayse Gok, Suner, Ali, Alici, Suleyman, Tarhan, Mustafa Oktay, Boruban, Cem, Oksuzoglu, Berna, and Urakci, Zuhat

Published
2014
Full Text
View/download PDF

17. Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer

Author

Topcu, Atakan, primary, Atci, Muhammed Mustafa, additional, Secmeler, Saban, additional, Besiroglu, Mehmet, additional, Ayhan, Murat, additional, Ozkan, Metin, additional, Bozkurt, Oktay, additional, Urakci, Zuhat, additional, Ay, Seval, additional, Geredeli, Caglayan, additional, Yasin, Ayse Irem, additional, and Turk, Haci Mehmet, additional

Published
2021
Full Text
View/download PDF

19. Mean platelet volume and platelet distribution width correlates with prognosis of early colon cancer

Author

Cihan, Sener, Sahin, Suleyman, Arici, Serdar, KARATAŞ, FATİH, Geredeli, Caglayan, Dikker, Okan, Demir, Cumhur, Samanci, Nilay Sengul, Sakin, Abdullah, Sakin, Aysegul, and Yasar, Nurgul

Abstract

Purpose: Several platelet indices have been linked to prognosis of various cancers, including metastatic colorectal cancer. The aim of this study was to investigate the prognostic effect of mean platelet volume (MPV) and platelet distribution width (PDW) in early colon cancer (CC) patients.

Published
2020

20. Effects of a Thermosensitive In Situ Gel Containing Mometasone Furoate on a Rat Allergic Rhinitis Model

Author

Bal, Oznur, ELKIRAN, EMİN TAMER, Gunaydin, Yusuf, Menekse, Serkan, Topcu, Turkan Ozturk, Urakci, Zuhat, Tastekin, Didem, BİLİCİ, Mehmet, Cihan, Sener, UYSAL, MÜKREMİN, TANRIVERDİ, ÖZGÜR, Gumus, Mahmut, Ustaalioglu, Bala Basak Oven, Suner, Ali, Cokmert, Suna, Hacibekiroglu, Ilhan, Aydin, Kubra, Isikdogan, Abdurrahman, Inal, Ali, Kodaz, Hilmi, Geredeli, Caglayan, SEZER, EMEL, Uncu, Dogan, Arpaci, Erkan, Ozturk, Banu, Odabas, Hatice, Duran, Ayse Ocak, Seker, Mehmet Metin, Inanc, Mevlide, and AKSOY, FADLULLAH

Subjects
Allergic Rhinitis, Nasal cavity, Ovalbumin, Mucociliary clearance, medicine.medical_treatment, Intraperitoneal injection, Mometasone furoate, Mucous membrane of nose, Pharmacology, Immunoglobulin E, Altuntas E., Yener G., DOĞAN R., Aksoy F., Aydin M. S. , Karatas E., -Effects of a Thermosensitive In Situ Gel Containing Mometasone Furoate on a Rat Allergic Rhinitis Model-, AMERICAN JOURNAL OF RHINOLOGY & ALLERGY, cilt.32, ss.132-138, 2018, 03 medical and health sciences, 0302 clinical medicine, Anti-Allergic Agents, Suspension, Immunoglobulin, medicine, Animals, Immunology and Allergy, Rats, Wistar, 030223 otorhinolaryngology, Administration, Intranasal, Thermosensitive, biology, business.industry, Intranasal Corticosteroids, Temperature, General Medicine, Eosinophil, Rhinitis, Allergic, Rats, Disease Models, Animal, Histopathological Evaluation, Treatment Outcome, medicine.anatomical_structure, Otorhinolaryngology, Rat model, biology.protein, Female, Nasal administration, Mucoadhesive, Nasal Cavity, In Situ Gel, business, Gels, Mometasone Furoate, 030217 neurology & neurosurgery, medicine.drug
Abstract

WOS: 000432900700002 PubMed ID: 29644886 Background: Mometasone furoate, one of the second generation intranasal corticosteroids, is currently used in suspension form due to its poor solubility. However, this is not favorable for nasal application because of the rapid elimination of the instilled drug from the nasal cavity by mucociliary clearance and delayed onset of action due to the slow dissolution of drug in suspension. Objective: The aim of this study was to determine the antiallergic effects of mucoadhesive thermosensitive in situ gel containing mometasone furoate that we developed previously to prolong the contact between the drug and nasal mucosa and to prevent drainage of the formulation in an ovalbumin-induced rat model of allergic rhinitis. Methods: An experimental allergic rhinitis model was developed in female Wistar albino rats by intraperitoneal injection of ovalbumin every 2 days for 14 days followed by its repeated intranasal instillation for 7 consecutive days. Intranasal instillation of ovalbumin was continued every other day for 14 days. Mometasone furoate in situ gel (5 mu g/10 mu l), mometasone furoate suspension (5 mu g/10 mu l), and physiological saline (10 ml) were administered into the bilateral nasal cavities from day 22 to day 35. Antiallergic effects were evaluated through histopathological evaluation, analysis of ovalbumin-specific serum immunoglobulin E, and a symptom score. Results: Mometasone furoate in situ gel significantly decreased the nasal symptoms and ovalbumin-specific serum immunoglobulin E level as compared with mometasone furoate suspension and physiological saline. Additionally, inflammatory histological symptoms such as mucosal edema, vascular dilatation, eosinophil infiltration, and loss of cilia within the nasal mucosa of allergic rhinitis model rats were remarkably improved with the treatment of mometasone furoate in situ gel. Conclusion: These results suggest that mometasone furoate in situ gel has a better therapeutic potential for the treatment of allergic rhinitis compared to mometasone furoate suspension. Scientific Research Project Coordination Unit of Istanbul University [41584]; TUBITAK (The Scientific & Technological Research Council of Turkey) [114S820, 1002] The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Scientific Research Project Coordination Unit of Istanbul University (Project Number: 41584) and Rapid Support Program (1002) of TUBITAK (The Scientific & Technological Research Council of Turkey (Project Number: 114S820).

Published
2018
Full Text
View/download PDF

21. Prognostic factors of patients who received chemotherapy after cranial irradiation for non-small cell lung cancer with brain metastases: A retrospective analysis of multicenter study (Anatolian Society of Medical Oncology)

Author

Inal, Ali, Kodaz, Hilmi, Odabas, Hatice, Duran, Ayse, Seker, Mehmet, İnanc, Mevlide, Elkıran, Emin, Gunaydın, Yusuf, Menekse, Serkan, Topcu, Turkan, Urakcı, Zuhat, Tastekin, Didem, Bilici, Mehmet, Cihan, Sener, Geredeli, Caglayan, Sezer, Emel, Uncu, Dogan, Arpacı, Erkan, Ozturk, Banu, Bal, Oznur, Uysal, Mukremin, Tanrıverdi, Ozgur, Gumus, Mahmut, Ustaalioglu, Bala Oven, Suner, Ali, Cokmert, Suna, Hacıbekiroglu, İLhan, Aydın, Kubra, and Isıkdogan, Abdurrahman

Subjects
Chemotherapy -- Usage, Radiotherapy -- Usage, Non-small cell lung cancer -- Care and treatment -- Prognosis, Brain tumors -- Research, Health
Abstract

Byline: Ali. Inal, Hilmi. Kodaz, Hatice. Odabas, Ayse. Duran, Mehmet. Seker, Mevlide. ?nanc, Emin. Elk?ran, Yusuf. Gunayd?n, Serkan. Menekse, Turkan. Topcu, Zuhat. Urakc?, Didem. Tastekin, Mehmet. Bilici, Sener. Cihan, Caglayan. [...]

Published
2018

22. The conversion of RAS status in metastatic colorectal cancer patients after first‐line biological agent treatment

Author

Arici, Serdar, primary, Hamdard, Jamshid, additional, Sakin, Abdullah, additional, Sengiz Erhan, Selma, additional, Atci, Muhammed Mustafa, additional, Cekin, Ruhper, additional, Saka, Burcu, additional, Köse, Emin, additional, Saydam, Tuba, additional, Geredeli, Caglayan, additional, Cihan, Sener, additional, and Bilici, Ahmet, additional

Published
2020
Full Text
View/download PDF

28. Is eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study

Author

ELKIRAN, EMİN TAMER, Koca, Sinan, Oruc, Zeynep, Kaplan, Muhammet Ali, Ercelep, Ozlem, Yuce, Ozlem, Isikdogan, Abdurrahman, Sevinc, Alper, Aytekin, Aydin, Ozaslan, Ersin, Geredeli, Caglayan, Sari, Nilgun Yildirim, Dogan, Mutlu, and TURAN, NEDİM

Subjects
skin and connective tissue diseases
Abstract

Purpose: This study aimed to analyze prognostic factors for survival and the reliability and the effectiveness of eribulin therapy in metastatic breast cancer (MBC) patients.

Published
2019

29. Prognostic Significance of Mean Platelet Volume on Local Advanced Non-Small Cell Lung Cancer Managed with Chemoradiotherapy

Author

Sakin, Abdullah, Secmeler, Saban, Arici, Serdar, Geredeli, Caglayan, Yasar, Nurgul, Demir, Cumhur, Aksaray, Ferdi, and Cihan, Sener

Subjects
Adult, Male, 0301 basic medicine, medicine.medical_specialty, Lung Neoplasms, lcsh:Medicine, Antineoplastic Agents, Gastroenterology, Article, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Mean platelet volume, Risk factor, lcsh:Science, Lung cancer, Survival analysis, Aged, Etoposide, Retrospective Studies, Aged, 80 and over, Multidisciplinary, medicine.diagnostic_test, business.industry, lcsh:R, Complete blood count, Retrospective cohort study, Chemoradiotherapy, Middle Aged, Prognosis, medicine.disease, Survival Analysis, Regimen, 030104 developmental biology, Female, lcsh:Q, Cisplatin, business, Mean Platelet Volume, 030217 neurology & neurosurgery
Abstract

Mean platelet volume (MPV), the most commonly used measure of platelet size, and is altered in patients with malignancies. The aim of this study was to investigate the effect of MPV on overall survival (OS) of patients with locally advanced (Stage IIIA/B) inoperable non-small cell lung cancer (NSCLC). This retrospective study included patients who received concomitant chemoradiotherapy (CCRT) with cisplatin + etoposide regimen due to locally advanced stage IIIA/B NSCLC. The study included a total of 115 cases, consisting of 110 (95.7%) male and 5 (4.2%) female patients. The mean age of the patients was 61.3 ± 10.4 (22–82) years. ROC curve generated by MPV for OS yielded an AUC of 0.746 (95% CI 0.659–0.833), (p 9 fL with a sensitivity of 74.4% and a specificity of 72.0%. In patients with stage IIIA, median OS was 45.0 months (95% CI 17.3–74.1) and 21 months (95% CI 10.6–31.3) in groups with MPV > 9.0 fL and ≤9.0 fL, respectively (p = 0.013). In patients with stage IIIB, median OS was 44.0 months (95% CI 13.8–60.6) and 16 months (95% CI 9.5–22.4) in groups with MPV > 9.0 fL and ≤9.0 fL, respectively (p = 0.036). ECOG performance score, total platelet count, and MPV were found as the most significant independent factors affecting survival (p

Published
2019
Full Text
View/download PDF

30. The Effect of Body Mass Index on Treatment Outcomes in Patients with Metastatic Non-Small Cell Lung Cancer Treated with Platinum-Based Therapy.

Author

Sakin, Aysegul, Sahin, Suleyman, Mustafa atci, Muhammed, Yasar, Nurgul, Demir, Cumhur, Geredeli, Caglayan, Sakin, Abdullah, and Cihan, Sener

Subjects
LUNG cancer prognosis, LUNG cancer, PLATINUM compounds, STATURE, CONFIDENCE intervals, BODY weight, CANCER chemotherapy, MULTIVARIATE analysis, METASTASIS, RETROSPECTIVE studies, TREATMENT effectiveness, CANCER patients, DESCRIPTIVE statistics, BODY mass index, ODDS ratio
Abstract

To investigate the effect of body mass index(BMI) on treatment outcomes and side-effect profile in metastatic non-small cell lung cancer(NSCLC) patients receiving platinum-based chemotherapy(ChT) in the first-line setting. This was a retrospective analysis of 233 NSCLC patients who were treated and followed up from 2008 through 2018. NSCLC patients who had metastatic disease at the time of diagnosis and were treated with platinum-based ChT in the first-line setting were included. The patients were divided into 2 groups based on the BMI as follows; BMI < 25 kg/m2 and BMI ≥ 25 kg/m2. This retrospective analysis enrolled 233 patients, 35 (15.0%) of whom were female. The BMI in 132 patients (56.2%) was < 25 kg/m2. The median age was 58 years (range, 21-90). Median progression-free survival(PFS) was 7 mo, in the patients with BMI ≥ 25 kg/m2 compared to 5.0 mo, in those with BMI < 25 kg/m2 (p = 0.032), with corresponding median overall survival(OS) durations of 12 vs. 9 mo, (p = 0.003). In multivariate analysis, ECOG PS 2, grade III histology, and brain or bone metastasis negatively affected OS, whereas BMI ≥ 25 kg/m2 positively affected OS. A high BMI prior to therapy in patients with NSCLC treated with platinum-based ChT in the first-line setting was associated with more favorable PFS and OS. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

46. Clinicopathologic and Prognostic Differences between Three Different Age Groups (Child/Adolescent, Young Adults, and Adults) of Colorectal Cancer Patients: A Multicentre Study

Author

Kaplan, Muhammet Ali, primary, Ozaydin, Sukru, additional, Yerlikaya, Halis, additional, Karaagac, Mustafa, additional, Gumus, Mahmut, additional, Cil, Timucin, additional, Yalcintas Arslan, Ülkü, additional, Ozdemir, Nuriye, additional, Sakin, Abdullah, additional, Bilici, Mehmet , additional, Koca, Dogan, additional, Uysal, Mukremin, additional, Dane, Faysal, additional, Sever, Özlem Nuray, additional, Seker, Mehmet Metin, additional, Oruc Seker, Zeynep, additional, Can, Mehmet Fatih, additional, Geredeli, Caglayan, additional, Aksoy, Asude, additional, Pilanci, Keziban Nur, additional, Ozturk Topcu, Turkan, additional, and Isikdogan, Abdurrahman, additional

Published
2019
Full Text
View/download PDF

48. The conversion of RAS status in metastatic colorectal cancer patients after first‐line biological agent treatment.

Author

Arici, Serdar, Hamdard, Jamshid, Sakin, Abdullah, Sengiz Erhan, Selma, Atci, Muhammed Mustafa, Cekin, Ruhper, Saka, Burcu, Köse, Emin, Saydam, Tuba, Geredeli, Caglayan, Cihan, Sener, and Bilici, Ahmet

Subjects
COLORECTAL cancer, METASTASIS, CANCER patients, LIVER metastasis, LIVER cancer
Abstract

Aim: The aim was to investigate the RAS discordance between initial and recurrent metastasectomy specimens in metastatic colorectal cancer (mCRC) patients treated with chemotherapy (CT) plus biological agents in a first‐line setting. Methods: Patients who had been treated with CT plus bevacizumab or cetuximab or panitumumab followed by R0 resection for potentially resectable colorectal cancer liver metastases were scanned. Among these, patients who developed resectable new metastases after a disease‐free interval longer than 6 months were included in the study. We compared the RAS mutation status between the first biopsy and the second metastasectomy specimen. Results: A total of 82 mCRC patients treated with CT plus biological agents in a first‐line setting were included in the study. The first biopsy assessment showed wild‐type RAS tumours in 39 (47.6%) patients and mutant RAS tumours in 43 (52.4%) patients. The mean time for new operable liver metastasis after R0 resection was 15.5 months. In the second metastasectomy specimens, the numbers of wild‐type and mutant RAS tumours were 30 (36.6%) and 52 (63.4%), respectively. The comparison with the first biopsy specimens showed RAS status conversions in 17 (20.7%) patients. Univariate comparison between patients with and without RAS status conversion revealed that grade, pathological T stage, wild‐type RAS tumour and longer biological agent use time in the first‐line treatment were significant factors for RAS conversion. Conclusion: Our results suggest that re‐biopsy is needed for an optimal second‐line treatment decision in mCRC patients regardless of backbone biological agent, especially in patients with wild‐type RAS mCRC. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

49. Factors affecting survival in operated pancreatic cancer: Does tumor localization have a significant effect on treatment outcomes?

Author

Sakin, Abdullah, Sahin, Suleyman, Sakin, Aysegul, Atci, Muhammed Mustafa, Arici, Serdar, Yasar, Nurgul, Demir, Cumhur, Geredeli, Caglayan, and Cihan, Sener

Subjects
PANCREATIC cancer, HEALTH outcome assessment, ADJUVANT treatment of cancer, CARCINOEMBRYONIC antigen, PROGNOSTIC tests
Abstract

OBJECTIVE: This study aims to investigate the factors affecting survival in operated pancreatic ductal adenocarcinoma (PDAC) and the possible prognostic effect of primary tumor localization on treatment outcomes. METHODS: In this study, 98 patients with curatively-operated PDAC, who were followed up and treated for the years 2008 through 2018, were enrolled. Metastatic and locally advanced stages and patients under 18 years of age were excluded from this study. Patients were divided into two groups based on the primary tumor localization as *head or *body/tail. RESULTS: Sixty-seven (68.3%) patients were male and 31 (31.7%) were female, with a median age of 62 years (range, 35-82 years). The numbers of patients with a primary tumor located in *head vs.*body/tail were 74 (75.4%) vs. 24 (24.6%), respectively. Patients with a primary tumor located in *head vs.*body/tail; median disease-free survival was 16.0 months vs. 13 months (p=0.972), respectively, with corresponding median overall survival was 25 months vs. 33 months (p=0.698). The level of carcinoembryonic antigen(CEA) at diagnosis (Hazard ratio[HR], 1.09 95%CI, 1.01-1.18), stage III disease (HR, 2.09 95%CI, 1.16-4.35), and receiving adjuvant treatment (HR, 0.20 95%CI, 0.09-4.34) were the independent predictors of survival. CONCLUSION: Our study revealed that high levels of CEA at diagnosis and stage III disease adversely affected the survival in non-metastatic PDAC patients, while receiving adjuvant therapy had a positive effect on survival. The findings suggest that primary tumor localization did not affect survival in operated PC patients. The results on this issue are still inconsistent and under debate in the literature. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

50. The impact of tumor regression grade on long-term survival in locally advanced rectal cancer treated with preoperative chemoradiotherapy.

Author

Sakin, Abdullah, Sahin, Suleyman, Sengul Samanci, Nilay, Yasar, Nurgul, Demir, Cumhur, Geredeli, Caglayan, Erhan, Selma Sengiz, Akboru, Mustafa Halil, and Cihan, Sener

Subjects
ADJUVANT treatment of cancer, CANCER patients, CELL lines, COMPARATIVE studies, CONFIDENCE intervals, LONGITUDINAL method, METASTASIS, MULTIVARIATE analysis, PATIENTS, PREOPERATIVE care, RECTUM tumors, SURGERY, SURVIVAL analysis (Biometry), TREATMENT effectiveness, RETROSPECTIVE studies, DESCRIPTIVE statistics, TUMOR grading, CHEMORADIOTHERAPY
Abstract

Purpose: The aim of this study is to investigate the prognostic effect of tumor regression grade (TRG) on long-term survival in locally advanced rectal cancer treated with preoperative chemoradiotherapy. Methods: Medical records of 182 patients with locally advanced rectal cancer, who were treated with preoperative chemoradiotherapy followed by surgery between 2002 and 2016, were retrospectively reviewed. TRG was classified into five categories based on the pathological response as follows – TRG1: no viable cancer cell, TRG2: single cancer cell or small groups of cancer cells, TRG3: residual tumor outgrown by fibrosis, TRG4: residual tumor outgrowing fibrosis, TRG5: diffuse residual tumor without regression. TRG1, (TRG2+TRG3), and (TRG4+TRG5) were grouped as complete response, intermediate response, and no response, respectively. Results: Of the 182 patients with locally advanced rectal cancer, 112 (61.5%) were male. The mean age was 54.4 (range, 25–87) years. The total number of patients in complete response, intermediate response, and no response group was 24 (13.2%), 105 (57.7%), and 53 (29.1%), respectively. The corresponding five-year relapse-free survival and overall survival rates were 79.8%–92.3%, 74.7%–79.4%, and 55.7%–55.8%, respectively (p < 0.05 for relapse-free survival, p < 0.05 for overall survival). According to ypTNM stage, there was no significant difference in relapse-free survival among TRG groups in ypStage I and II patients (p > 0.05). In ypStage III patients, relapse-free survival was 62 months in no response group vs. not reached in intermediate response group (p < 0.05). According to the ypTNM, there was no significant difference in overall survival among TRG groups in ypStage I, II, and III patients (p > 0.05). In the multivariate analysis, pathological complete response was found to be an independent variable for relapse-free survival and overall survival (hazard ratio (95% confidence interval), 0.34 (0.17–6.77), 0.39 (0.18–0.83), respectively). Conclusion: This study showed that patients with pathological complete response to preoperative chemoradiotherapy had longer relapse-free survival and overall survival rates than those with residual disease. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results